ReCor Medical Announces New Lead Investor and Upcoming Hypertension Trial

PALO ALTO, California, April 11, 2015 /PRNewswire/ — ReCor Medical, Inc., a Palo Alto– and Amsterdam-based medical device firm, announced today a Series D investment of approximately $15M led by Otsuka Holdings Co., Ltd., the parent company of Otsuka Pharmaceutical and the Otsuka group of healthcare companies. Otsuka Holdings, one of the leading healthcare groups in Japan, joined Sofinnova Partners in the Series D round.  In addition, ReCor has met with the US FDA regarding a new randomized controlled trial of its Paradise Renal Denervation (“RDN”) System in hypertensive patients to demonstrate its effect on blood pressure in conjunction with, and in the absence of, hypertensive drug therapy. The Company is planning to conduct the new study at 20 – 25 sites in the US and EU.

“The Series D investment led by Otsuka Holdings shows renewed interest in the renal denervation field and confidence in our ultrasound-based Paradise System,” commented Andrew M. Weiss, President and CEO of ReCor. “We are pleased to have attracted investment from one of Japan’s premier healthcare groups.  This new relationship will support our upcoming US clinical studies and open new potential for our technology in Japan and greater Asia.  We are pleased to be positioned alongside Boston Scientific and Medtronic, who have also recently announced new clinical trials in renal denervation for the treatment of hypertension.”

“ReCor believes that our Paradise technology may have a distinct advantage over competitive RF-based RDN systems by providing active vessel protection and 360 degree energy delivery. We believe that we can demonstrate an important clinical effect in hypertension patients with the Paradise system,” added Mano Iyer, ReCor COO and co-founder, “We are working with leading hypertension experts and interventionalists to finalize our clinical study design, and plan to begin enrollment in the second half of 2015.”

ReCor is a Palo Alto– and Amsterdam-based clinical-stage medical device company with a proprietary ultrasound system for renal denervation called the Paradise System. Paradise, which has CE mark, uses 6Fr or 5Fr catheters for intravascular denervation of the renal nerves by combining water-based cooling of the renal artery and high intensity ultrasound energy for circumferential renal nerve ablation. The Paradise System has been studied in 3 clinical trials, and has been used in over 200 patients. For additional information see: www.recormedical.com.

Otsuka Holdings Co., Ltd. is the holding company of the Otsuka group, a global healthcare group headquartered in Tokyo, Japan. With operations in pharmaceuticals, nutraceuticals, medical devices and other health-related businesses, the group generated worldwide sales of approximately JPY1,224 billion in the fiscal year ended December 2014. Under its corporate philosophy, “Otsuka – people creating new products for better health worldwide”, the Otsuka Group conducts research, development, manufacturing and marketing of innovative products that are uniquely positioned to provide advanced therapy, improve quality of life and support a healthy lifestyle. The Otsuka Group consists of 119 companies worldwide with 29,482 employees. Additional information can be found on http://www.otsuka.com/en/

Continue Reading

China Jo-Jo Drugstores Announces Change in Auditing Firm

HANGZHOU, China, April 10, 2015 /PRNewswire/ — China Jo-Jo Drugstores, Inc. (“China Jo-Jo“, or the “Company”) (NASDAQ CM: CJJD), a leading China-based retail and wholesale distributor of pharmaceutical and health care products through its own online and retail pharmacies, today announced that it has engaged BDO China Shu Lun Pan Certificated Public Accountants LLP (“BDO China”) as the Company’s new independent auditing firm effective on April 7, 2015. The appointment of BDO China was approved by the Company’s Audit Committee.

BDO is one of the leading global accounting firms with member firms in over 144 countries. BDO China was founded in 1927 and is one of the earliest and most influential accounting firms in China. BDO China’s clients include over 300 listed companies, over 300 IPO companies, and more than 2,000 enterprises with foreign investments. The companies BDO provides services to cover a wide range of sizes and industries including large national enterprises, state-owned companies, commercial banks, securities companies, futures brokerage, insurance, trusts and funds.

With BDO China team’s large local presence and its well-established reputation, the Company believes that BDO China is well qualified to become its independent auditing firm. The Company does not believe that the change of auditor will affect the timely filing of its annual report on Form 10-K for the year ending March 31, 2015.

For more information on the Company’s change in auditing firm, please refer to the Company’s Form 8-K filed on April 7, 2015:

http://www.sec.gov/Archives/edgar/data/1413263/000121390015002561/f8k040715_chinajojo.htm

About China Jo-Jo Drugstores, Inc.

China Jo-Jo Drugstores, Inc., through its own retail drugstores, wholesale distributor and online pharmacy, is a leading retailer and wholesale distributor of pharmaceutical and healthcare products in China. As of December 31, 2014, the Company had 60 retail pharmacies in Hangzhou. The Company’s wholesale subsidiary not only supplies its retail stores, but also distributes drug and other healthcare products to other drugstores and drug vendors. The Company routinely posts important information on its corporate websites at www.jiuzhou-drugstore.com (Chinese) and www.chinajojodrugstores.com (English).

Forward Looking Statement

Statements in this press release regarding the Company that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actual future events or results to differ materially from such statements. Any such forward-looking statements, including, but not limited to, financial guidance, are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as “believe,” “expect,” “estimate,” “may,” “will,” “should,” “project,” “plan,” “seek,” “intend,” “anticipate,” the negatives thereof, or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. It is routine for the Company’s internal projections and expectations to change as the quarter and year progresses, and therefore it should be clearly understood that the internal projections and beliefs upon which the Company bases its expectations may change. Although these expectations may change, the Company is under no obligation to inform you if they do. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of numerous factors, including the risks associated with the effect of changing economic conditions in the People’s Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products. Readers are referred to the reports and documents filed from time to time by the Company with the Securities and Exchange Commission for a discussion of these and other important risk factors that could cause actual results to differ from those discussed in forward-looking statements.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/china-jo-jo-drugstores-announces-change-in-auditing-firm-300064019.html

Continue Reading

BNC105 Biomarker Data to Be Presented at Asian Oncology Conference

ADELAIDE, Australia, April 10, 2015 /PRNewswire/ — Bionomics Limited (ASX: BNO, OTCQX: BNOEF) today announced that it will present a poster with new data on the DisrupTOR-1 trial of BNC105 in patients with metastatic renal cancer at the 7th Asian Oncology Summit being held from April 10-12, 2015 in Shanghai, China.

The poster will be presented by Dr. Jeremy Simpson, Vice President, Clinical Development at Bionomics, and is entitled, A phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC): Results of the randomized phase II DisrupTOR-1 trial. The Poster Walk session is during the Welcome Reception on Friday, April 10th, 2015 at 5:45 p.m. CST in the Mandarin Hall of the Oriental Riverside Hotel and Convention Centre .

The data identify ferritin and IL-8 as two baseline biomarkers that correlate with an improved progression free survival (PFS) in patients. Eighty nine percent of patients expressing higher plasma levels of ferritin and lower plasma levels of IL-8 at baseline were disease progression-free at six months. The data show that biomarker-based patient selection has the potential to optimise clinical outcomes in the treatment of renal cancer. There are 6.3 new cases of renal cancer and 1.7 deaths per 100,000 people in Asia each year.

BNC105 is a novel compound being developed as a vascular disrupting agent (VDA) for the treatment of cancer. VDAs are drugs that disrupt the blood vessels that nourish tumours. This approach has a number of advantages over classical chemotherapy, including stronger impact on tumour cell death, applicability to a wider variety of cancers, and lowered risk of the emergence of therapy-resistant tumour cells.

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited

Monsoon Communications

Stern IR

Dr Deborah Rathjen

Rudi Michelson

Beth DelGiacco

CEO & Managing Director

+61 (0)3 9620 3333

+1 (212) 362 1200

+61 (0)8 8354 6101

rudim@monsoon.com.au

beth@sternir.com

0418 160 425

drathjen@bionomics.com.au

About Bionomics Limited
Bionomics (ASX: BNO) is a biopharmaceutical company that discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, memory loss and pain. Its oncology approach includes cancer stem cell therapeutics as well as vascular disruption in solid tumours.

Bionomics’ discovery and development are driven by its four proprietary technology platforms: MultiCore®, a diversity orientated chemistry platform for the discovery of small molecule drugs; ionX® , a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system; Angene®, a drug discovery platform that incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels); and CSC Rx Discovery™, which identifies antibody and small molecule therapeutics that inhibit the growth of cancer stem cells. These platforms drive Bionomics’ pipeline and underpin its established business strategy of securing partners for its key compounds. Bionomics’ partners include Merck & Co.

www.bionomics.com.au

Factors Affecting Future Performance
This announcement contains “forward-looking” statements within the meaning of the United States’ Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics’ development candidates BNC105, BNC210, BNC101 and BNC375, our acquisition of Eclipse Therapeutics and ability to develop products from their platform, its licensing deals with Merck & Co, drug discovery programs and pending patent applications are deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to our available funds or existing funding arrangements, a downturn in our customers’ markets, our failure to introduce new products or technologies in a timely manner, Merck’s decisions to continue or not to continue development of partnered compounds, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Results of studies performed on competitors’ products may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bnc105-biomarker-data-to-be-presented-at-asian-oncology-conference-300063987.html

Continue Reading

IBA and Toshiba Sign Strategic Partnership in Particle Therapy

LOUVAIN-LA-NEUVE, Belgium and TOKYO, April 9, 2015 /PRNewswire/ —

  • Collaboration signed to enhance access to proton therapy and carbon therapy worldwide 
  • Toshiba Medical Systems Corporation to become IBA’s Proteus®ONE distributor in Japan 
  • IBA to become Toshiba’s carbon therapy agent outside Japan 

IBA (Ion Beam Applications S.A.) and Toshiba Corporation (Tokyo: 6502) today announce the signing of a global collaboration to expand access to advanced particle therapy worldwide. Toshiba Medical Systems Corporation will become the distributor in Japan for Proteus®ONE, IBA’s compact single-room proton therapy solution, and IBA will become the agent for Toshiba’s Carbon Therapy Solutions outside Japan.

Photo: http://photos.prnewswire.com/prnh/20150409/739058

IBA and Toshiba will collaborate on activities such as customer education for Proteus®ONE and Toshiba’s carbon therapy solutions.

The collaboration will also enable both organizations to mutually leverage their Operation and Maintenance (O&M) services.

Olivier Legrain, Chief Executive Officer of IBA commented: “This is an important step for IBA. A closer collaboration with a company of Toshiba’s caliber and leadership will accelerate the expansion of proton therapy in Japan and the introduction of Toshiba’s carbon therapy across the world. Carbon ion therapy is particularly suitable for treating radio-resistant tumors and allows for dose escalation, which is recommended in a number of clinical applications. Through this new collaboration, IBA will further strengthen its world leading position in proton therapy and will reaffirm its leading position in the delivery of the latest innovative cancer therapies worldwide.”

Satoshi Tsunakawa, Chief Executive Officer of Healthcare Company, Toshiba Corporation, said: “Proton and carbon therapies are among the most exciting technological advancements in the treatment of cancer. Toshiba looks forward to collaborating with IBA to enhance access to best-in-class technologies for both proton and carbon therapy centers. Guided by the principles of The Basic Commitment of the Toshiba Group, “Committed to People, Committed to the Future,” this collaboration will give both our companies an enhanced set of tools to provide the best cancer treatment technologies.”

About Proton and Carbon Therapy 

Proton Therapy is considered an advanced and targeted cancer radiotherapy treatment due to its superior dose distribution and fewer side effects. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor, sparing healthy surrounding tissue. Higher doses can be delivered to the tumor without increasing the risk of side effects and long-term complications, thereby improving patient outcomes and quality of life.

Carbon ions not only have similar physical characteristics as protons, they have also a higher radiobiological effect compared to photon and proton, which could lead to shorter treatment courses and improved patient outcomes.

About IBA 

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full scale proton therapy centers as well as compact, single room systems.  In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1100 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets.  IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: http://www.iba-worldwide.com

About Toshiba 

Toshiba Corporation, a Fortune 500 company, channels world-class capabilities in advanced electronic and electrical products and systems into five strategic business domains: Energy & Infrastructure, Community Solutions, Healthcare Systems & Services, Electronic Devices & Components, and Lifestyles Products & Services. Guided by the principles of The Basic Commitment of the Toshiba Group, “Committed to People, Committed to the Future,” Toshiba promotes global operations towards securing “Growth Through Creativity and Innovation” and is contributing to the achievement of a world in which people everywhere live in a safe, secure and comfortable society.

Founded in Tokyo in 1875, today’s Toshiba is at the heart of a global network of over 590 consolidated companies employing over 200,000 people worldwide, with annual sales surpassing 6.5 trillion yen (US$63 billion). To find out more about Toshiba, visit http://www.toshiba.co.jp/index.htm

Toshiba newly formed its Healthcare Company last August to focus its healthcare business as one of three pillars of its overall business. By combining diagnosis imaging technology provided by Toshiba Medical Systems and accelerator and super conducting technology derived from nuclear business, Toshiba is delivering Heavy Ion Therapy system for cancer treatment. Toshiba has been contributing to Japanese National Institute of Radiological Sciences and Kanagawa Cancer Center.

For further information please contact:  

IBA
Jean-Marc Bothy
Chief Financial Officer
Tel: +32-10-47-58-90

Thomas Ralet
Vice-President Corporate Communication
+32-10-47-58-90
communication@iba-group.com

For media and investor enquiries:
Consilium Strategic Communications
Amber Bielecka, Matthew Neal, Jessica Hodgson and Ivar Milligan
+44(0)20-3709-5700
IBA@consilium-comms.com

Rx Communications Group (US)
Melody Carey
+ 1-917-322-2571
mcarey@RxIR.com

Toshiba Press Contact:
Yukihito Uchida
Masumi Fukuoka
Tatsuro Oishi
PR & IR Office, Toshiba Corporation
+81-3-3457-2100
media.relations@toshiba.co.jp

Continue Reading

Directors from Chinese and American Hospitals Meet to Discuss Big Data Applications at Harvard Medical School

Market Value of China’s Independent Medical Laboratory Market on Track to Reach CNY32 Billion

BOSTON, April 9, 2015 /PRNewswire/ — At this year’s recently held National People’s Congress and Chinese Political Consultative Conference (NPC & CPPCC), CPPCC national committee member and Chinese Academy of Engineering fellow Wu Yiling proposed that China shift the current focus on dealing with chronic diseases from treatment to prevention. “According to statistics collected by the World Health Organization, the incidence of chronic diseases is clearly related to the maturity of the local prevention and treatment systems. The incidence of major chronic diseases such as cardio-cerebrovascular disease in western developed countries is on the decline, while, during the last 10 years, the rates of morbidity and mortality related to cardio-cerebrovascular disease, diabetes and other chronic conditions in China continues to soar as the country’s investment in the healthcare system in terms of the prevention and treatment of such diseases is neither sufficient nor complete. Wu pointed out that if we cannot bring the incidence of these diseases under control, they will become be a huge burden to Chinese society and to families across the nation, as well as adversely impact to significant degree China’s plan for a full realization of the government’s strategy for the overall betterment of the society at large.

The proposal is universally welcomed by both the domestic and foreign medical communities. The focus of discussions going on at Harvard Medical School is on how big data is a core component of the solution and how it can be leveraged to study the pathogenesis of each disease, how to better prevent and treat each disease as well as manage the related medical expenditure.

Co-hosted by Massachusetts Medical International Corporation (MMIC), the Association of Chinese American Physicians and the Harvard Medical School Chinese Scholars and Scientists Association, the Sino-US Hospital Directors 2015 Summit at Harvard was held from March 27th to 30th, 2015. The summit kicked off with discussions concerning translational medicine and the application of big data in hospital management, then moved on to the main themes of the latest global trends in biomedical research, the application of its technological achievements as well as the world’s most advanced models for the management of a hospital.

Liang Yaoming, Chairman and Chief Executive Officer of Kingmed Diagnostics, a leading independent Chinese provider of clinical and laboratory testing services, was invited to participate in the summit and delivered a keynote speech on the development of independent medical laboratories in China. Liang believes that China’s huge population base can provide an endless stream of yet untapped data points. As China’s largest independent medical testing provider, Kingmed Diagnostics has accumulated nearly 80 million specimens during the last 6 years. As the number of specimens continued to build, Kingmed Diagnostics realized the value of the application of big data in analyzing such a large collection, which, in turn, attracted a great deal of attention from medical practitioners.

At the same time, Liang disclosed that with the better application of big data of the healthcare system, the rapid development of genomics research and whole-genome sequencing technology as well as the development of Internet-mediated direct-to-consumer medical services, China’s independent medical testing market is expanding rapidly, with the market value on track to reach 32 billion yuan in 2020.

Hospitals in China and America mining the potential of big data from information yielded by independent medical laboratories

The rapid modernization of collection methods of medical and healthcare information opened the door to big data applications. The next step, one that is drawing more and more attention, is how to use this information to improve hospital management as well as medical services, scientific research and education.

The Sino-US Hospital Directors 2015 Summit at Harvard currently has the highest profile and is considered the most authoritative among Sino-US health summits. Healthcare policy makers, top managers, hospital directors from leading healthcare facilities across the U.S. and China as well as healthcare industry experts, such as Partners HealthCare System chairman Dr. David F. Torchian and Economic Development Committee of the United Nations deputy director Simmon Chu, held in-depth discussions on several academic topics including, for both the US and Chinese healthcare systems, the development strategy for healthcare, the application of medical big data in hospitals and the best practice for hospital management.

Kingmed Diagnostics, the sole Chinese independent medical laboratories at the summit, caught the attention of all parties. Kingmed Diagnostics delivered a keynote speech at the “Best Practice for Hospital Management” section. Served as a necessary supplement to current healthcare resources, the independent laboratories have received wide attention and acclaim from professional peers worldwide. The independent laboratories have already been applying big data technologies to data collection and biobank building, and the potential that this big data can provide is being watched seriously by hospital practitioners.

Because of the enormous advantage of scales, the independent laboratories have a huge number of testing data gathered, including patients with different types of disease, different locations, gender and age. Analyzing the data can help to explore and understand the pathogenesis, the trends of disease incidence and effectiveness of different treatments, ultimately playing an active role in disease prevention, treatment and monitoring.

Liang explained that during the last six years, Kingmed Diagnostics has collected nearly 80 million of specimens, and their laboratories test about 40,000-50,000 specimens a day. Since 2008, the number of annual specimens analyzed has increased by more than 50%, By cooperating with more than 16,000 medical institutions, Kingmed provide diagnostic service to a population of 1.3 billion in more than 30 provinces.

Kingmed Diagnostics is looking for partnership opportunities with the international and domestic institutions who are interested in big data research and application. At the summit, Liang revealed that the company hopes to find cooperation opportunities in genomics, tele-medicine, mobile health, big data and personalized medicine as well as in related areas. To provide tangible value that can serve for disease monitoring and better healthcare, Kingmed Diagnostics is actively extracting the medical value from big data, an important milestone on the way to the beneficial use of big data across China’s healthcare sector.

China’s independent laboratory market has developed rapidly

According to available data, on a global scale, independent medical testing laboratories account for 38%, 50% and 67% of the market share in North America, Europe and Japan respectively, while only accounting for a 2% share in China. The huge market potential in the underserved country is waiting for exploration.

At the summit Liang said that China’s aging population, urbanization and the expansion of health insurance coverage is fostering the acceleration of growth of the independent laboratory market. Liberalization of the market, encouraged private investment on healthcare, the development of private hospitals, the optimized healthcare resource allocation and the cost-efficiency controls of hospitals further stimulate the development of such market. The application of big data of healthcare systems, development of genomics and whole-genome sequencing and the development of Internet-mediated direct-to-consumer medical services, all contribute to the scalability of the independent laboratory market. According to Kingmed Diagnostics’ internal data modeling, by 2020 China’s independent laboratory market scale will be worth 32 billion yuan ($5.15 billion). Currently the top 5 providers account for 76% of the entire independent laboratory market, with Kingmed Diagnostics in the lead.

With independent diagnostic testing service as the main business, Kingmed Diagnostics also provide other services including clinical trials, physical examinations, food and hygiene testing, scientific research services, judicial authentication as well as Internet-mediated direct-to-consumer medical services. Kingmed owns 23 provincial central labs, and now offers more than 1600 tests. It provides diagnostic services to 1.3 billion of population across China by collaborating with more than 16,000 medical institutions in 30 provinces, and tests nearly 30 million specimens annually. In 2014, the company achieved revenues of 1.855 billion yuan, up 32.3% from a year earlier. The immense database of medical information is drawing the attention of industry leaders who see how the analysis of the data can serve to improve hospital management and enhance disease prevention and control. Liang revealed, with another 4 new provincial laboratories coming on stream soon, Kingmed Diagnostics will leverage its network of soon to be 27 provincial laboratories to comprehensively examine and start the build out of innovative businesses related to the application of medical big data.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/directors-from-chinese-and-american-hospitals-meet-to-discuss-big-data-applications-at-harvard-medical-school-300063567.html

Continue Reading

VolitionRx Adds Three New Laboratory Automation Systems to Expedite Sample Analysis for its Large Ongoing Clinical Trials

Strategic investment to accelerate development of NuQ? colorectal cancer detection test

NAMUR, Belgium, April 9, 2015 /PRNewswire/ — VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that it has procured three additional Tecan EVO200 automated liquid handling systems (automated laboratory robots) to expedite analysis of samples for the ongoing large clinical trials evaluating its NuQ® cancer detection platform. By increasing capacity to four automated systems, throughput and rate of sample analysis will be greatly increased, enabling faster development of the Company’s NuQ® tests.

Cameron Reynolds, Chief Executive Officer of VolitionRx, remarked, “This budgeted investment greatly supports our Company’s strategic decision to maximize the speed and efficiency of our ongoing large clinical trials. The use of four automated systems will support the generation of extensive amounts of data and allow for faster study timelines to full data readouts. We expect that this increased data generation capacity will result in more scientific publications, quicker access to CE mark in Europe and an overall accelerated approach to regulatory pathways worldwide.”

Using its first installed robot, VolitionRx has recently completed the analysis of a first NuQ® assay on the complete set of 4,800 blood samples for its large retrospective, symptomatic population colorectal cancer study in collaboration with Hvidovre Hospital, University of Copenhagen, Denmark. Procuring three new Tecans allows the Company to dedicate one robot to this study, and VolitionRx now hopes to complete one NuQ® assay per month on the full data set for the 4,800-patient cohort. At this capacity, the Company expects to finalize its analysis and determine an initial NuQ® colorectal cancer panel during the second half of 2015.

Gaetan Michel, PhD, Chief Operations Officer of Belgian Volition, commented, “The fully-dedicated Tecan platform currently allows us to run analysis of approximately 5,000 samples per month per robot. The reproducibility and robustness of these automated assays is extremely encouraging and will allow for optimal output of reliable large scale results. We are currently further optimizing the platform process to reach a 50 percent capacity increase to 7,500 samples per month per robot.”

VolitionRx Chief Scientific Officer Dr. Jake Micallef added, “Over the past five years, since VolitionRx was established, we have manually processed approximately 30,000 samples across all our studies, in multiple cancers. Due to the significant increase in the number of clinical studies we now have underway, and our constant development of new biomarkers for new assays, we determined that it was essential to make a step change in our processing capabilities through additional automated platforms. This investment will allow us to reach an impressive capacity of 30,000 assays per month, approximately the same amount as we have completed in total. The first robot is fully up and running and all four are due to be delivered by the end of April and should be fully operational by the end of May.”

The NuQ® tests utilize the Company’s proprietary Nucleosomics® technology platform, which identifies and measures circulating nucleosome structures for the presence of epigenetic cancer and signals within the blood.

VolitionRx has developed a suite of NuQ® assays for more than 20 different epigenetic structures on nucleosomes. These assays use two antibodies. The first antibody is attached to a plastic surface and binds to nucleosomes. The second antibody is chemically detectable and binds to the epigenetic structure of interest contained within the nucleosome. When blood is added to the antibody-coated plastic plate, nucleosomes in the blood bind to the first antibody. The second antibody is then added and can only be chemically detected if nucleosomes containing the epigenetic structure of interest are present. The NuQ® assay uses less than a single drop of blood to measure nucleosomes that contain the epigenetic structure of interest and the level of these nucleosomes is different in the blood of cancer patients than in healthy people. Each NuQ® cancer test uses a combination of 4-5 of these proprietary assays to form a “panel” test.

Clinical trials assessing the effectiveness of VolitionRx’s assays include:

Colorectal cancer:

  • A 4,800 patient retrospective symptomatic population study (Hvidovre Hospital, University of Copenhagen, Denmark)
  • A 14,000 patient prospective screening study (Hvidovre Hospital, University of Copenhagen, Denmark)
  • A 250 patient prospective study (CHU-UCL Mont Godinne Hospital, Belgium)

Lung cancer:

  • A 600 patient prospective confirmatory study (University Hospital, Bonn, Germany)

Prostate cancer:

  • A retrospective study to establish the efficacy of VolitionRx’s NuQ® tests to distinguish anaplastic prostate cancer, a particularly aggressive form of the disease, from typical castration resistant prostate cancer (CRPC), the less aggressive form (MD Anderson, Texas)
  • A 120-patient prospective feasibility study (ImmuneHealth, Belgium)

Ovarian cancer:

  • A 40-patient prospective feasibility study (Singapore General Hospital, Singapore)

20 most prevalent cancers

  • A 4,000 patient prospective study that involves patients with the 20 most prevalent cancers at University Hospital in Bonn, Germany

Endometriosis

  • A prospective study to assess VolitionRx’s NuQ® tests for the diagnosis of endometriosis (the University of Oxford, United Kingdom)

For more information about Tecan’s liquid handling system (robot) please see http://www.tecan.com/platform/apps/product/index.asp?MenuID=2694&ID=5270&Menu=1&Item=21.1.8

About VolitionRx

VolitionRx is a life sciences company focused on developing diagnostic tests for cancer and other conditions. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present.

VolitionRx’s goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx’s research and development activities are currently centered in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide.

Visit VolitionRx’s website (http://www.volitionrx.com) or connect with us via Twitter, LinkedIn, Facebook or YouTube.

Media Contacts

Charlotte Reynolds, VolitionRx
Charlotte.Reynolds@volitionrx.com
Telephone: +44 (0) 795 217 7498

Kirsten Thomas, The Ruth Group
kthomas@theruthgroup.com
Telephone: +1 (646) 536-7014

Investor Contacts

Scott Powell, Investor Relations
S.Powell@volitionrx.com
Telephone: +1 (646) 650-1351

Lee Roth, The Ruth Group
lroth@theruthgroup.com
Telephone: +1 (646) 536-7012

Safe Harbor Statement

Statements in this press release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “optimizing,” “potential,” “goal,” “suggests” and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of the Company’s bodily-fluid-based diagnostic tests as well as the Company’s ability to develop and successfully commercialize such test platforms for early detection of cancer. The Company’s actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if we fail to develop and commercialize diagnostic products, we may be unable to execute our plan of operations. Other risks and uncertainties include the Company’s failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in the Company’s development pipeline or any other diagnostic products the Company might develop; the Company will face fierce competition and the Company’s intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as other documents that the Company files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, the Company does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/volitionrx-adds-three-new-laboratory-automation-systems-to-expedite-sample-analysis-for-its-large-ongoing-clinical-trials-300063483.html

Continue Reading